Is AGITATION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed AGITATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported AGITATION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and AGITATION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause AGITATION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes AGITATION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if AGITATION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing AGITATION: 2
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where AGITATION is a reported side effect: 0.0601%

FDA reports of any drug causing AGITATION : 28308
Average percentage for all medicated patients where AGITATION is reported as a complication: 0.1774%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with AGITATION:

CHANTIX (2665 patients)
SEROQUEL (2611 patients)
PAXIL (1548 patients)
ASPIRIN (1320 patients)
XANAX (1038 patients)
LORAZEPAM (1025 patients)
CYMBALTA (1008 patients)
ZYPREXA (978 patients)
RISPERDAL (901 patients)
ZOLOFT (874 patients)
EFFEXOR (834 patients)
CLONAZEPAM (812 patients)
LYRICA (791 patients)
DIAZEPAM (775 patients)
OMEPRAZOLE (759 patients)
PAROXETINE HCL (754 patients)
NEURONTIN (752 patients)
LEXAPRO (728 patients)
CLOZARIL (701 patients)
CITALOPRAM HYDROBROMIDE (659 patients)
ATIVAN (651 patients)
ACETAMINOPHEN (637 patients)
LISINOPRIL (636 patients)
PROZAC (629 patients)
EFFEXOR XR (621 patients)
NAMENDA (621 patients)
LAMICTAL (618 patients)
SIMVASTATIN (588 patients)
OLANZAPINE (587 patients)
KLONOPIN (580 patients)
NEXIUM (574 patients)
ABILIFY (568 patients)
DEPAKOTE (557 patients)
AMBIEN (554 patients)
SYNTHROID (532 patients)
OXYCONTIN (518 patients)
LIPITOR (511 patients)
HALDOL (497 patients)
EXELON (495 patients)
WELLBUTRIN (493 patients)
MIRTAZAPINE (492 patients)
SINGULAIR (487 patients)
GEODON (468 patients)
RISPERIDONE (461 patients)
LEVOTHYROXINE SODIUM (460 patients)
LITHIUM CARBONATE (460 patients)
LASIX (451 patients)
FUROSEMIDE (449 patients)
VALIUM (444 patients)
GABAPENTIN (443 patients)
CLOZAPINE (442 patients)
METFORMIN HCL (440 patients)
SEROQUEL XR (437 patients)
ATENOLOL (429 patients)
ALPRAZOLAM (428 patients)
STRATTERA (427 patients)
VIOXX (424 patients)
TRAZODONE HCL (416 patients)
HALOPERIDOL (409 patients)
IBUPROFEN (405 patients)
MORPHINE (397 patients)
PREDNISONE (397 patients)
FLUOXETINE (390 patients)
TRAMADOL HCL (379 patients)
PRISTIQ (377 patients)
HEPARIN SODIUM INJECTION (376 patients)
FENTANYL (371 patients)
DURAGESIC-100 (367 patients)
MORPHINE SULFATE (362 patients)
CELEXA (361 patients)
ALBUTEROL (357 patients)
AMITRIPTYLINE HCL (354 patients)
KEPPRA (342 patients)
HYDROCHLOROTHIAZIDE (338 patients)
ZOCOR (334 patients)
OXYCODONE HCL (333 patients)
WELLBUTRIN XL (333 patients)
PROTONIX (323 patients)
PLAVIX (319 patients)
FOLIC ACID (317 patients)
PRILOSEC (316 patients)
FOSAMAX (316 patients)
ARICEPT (314 patients)
TEGRETOL (306 patients)
VICODIN (290 patients)
DIGOXIN (283 patients)
CELEBREX (276 patients)
DEXAMETHASONE (276 patients)
PERCOCET (275 patients)
ZOMETA (275 patients)
TOPROL-XL (273 patients)
ACCUTANE (268 patients)
POTASSIUM CHLORIDE (267 patients)
LAMOTRIGINE (267 patients)
VALPROATE SODIUM (265 patients)
NORVASC (259 patients)
TRILEPTAL (259 patients)
PREVACID (256 patients)
REMERON (252 patients)
COUMADIN (248 patients)
BENADRYL (237 patients)
CLONIDINE (234 patients)
CHAMPIX (234 patients)
TOPAMAX (234 patients)
CONCERTA (230 patients)
INSULIN (230 patients)
ALLOPURINOL (227 patients)
METOPROLOL TARTRATE (227 patients)
SEROXAT (227 patients)
ALCOHOL (226 patients)
RITALIN (223 patients)
SERTRALINE HYDROCHLORIDE (220 patients)
ADVAIR DISKUS 100/50 (219 patients)
VITAMIN D (216 patients)
PAXIL CR (212 patients)
LEVAQUIN (211 patients)
RIVOTRIL (211 patients)
PROPOFOL (210 patients)
RANITIDINE (208 patients)
LORTAB (207 patients)
CIPROFLOXACIN (206 patients)
MODOPAR (206 patients)
ESCITALOPRAM (202 patients)
WARFARIN SODIUM (201 patients)
PAROXETINE HYDROCHLORIDE (200 patients)
LANTUS (199 patients)
STALEVO 100 (199 patients)
QUETIAPINE (198 patients)
METHOTREXATE (195 patients)
BACLOFEN (195 patients)
ZOLPIDEM (193 patients)
METFORMIN (193 patients)
LEVOXYL (192 patients)
TEMAZEPAM (190 patients)
CARBAMAZEPINE (190 patients)
CRESTOR (190 patients)
VENLAFAXINE HCL (190 patients)
RAMIPRIL (189 patients)
NITROGLYCERIN (188 patients)
ZOPICLONE (187 patients)
PROPRANOLOL (186 patients)
ZOFRAN (184 patients)
QUETIAPINE FUMARATE (183 patients)
SOMA (183 patients)
AMLODIPINE (183 patients)
MULTI-VITAMINS (183 patients)
NAPROXEN (181 patients)
VALPROIC ACID (181 patients)
LIORESAL (179 patients)
ZANTAC (176 patients)
ALLEGRA (175 patients)
SPIRONOLACTONE (174 patients)
MEMANTINE HCL (174 patients)
ATARAX (174 patients)
CLARITHROMYCIN (174 patients)
CALCIUM (173 patients)
PREDNISOLONE (171 patients)
ALL OTHER THERAPEUTIC PRODUCTS (170 patients)
BACTRIM (169 patients)
MIDAZOLAM HCL (169 patients)
BUPROPION HCL (169 patients)
PREDNISONE TAB (168 patients)
ZYRTEC (168 patients)
ACYCLOVIR (165 patients)
PAROXETINE (165 patients)
LITHIUM (164 patients)
METOCLOPRAMIDE (163 patients)
ZOLPIDEM TARTRATE (162 patients)
VYVANSE (161 patients)
BUSPAR (159 patients)
DEPAKENE (159 patients)
LUNESTA (158 patients)
HUMIRA (157 patients)
FLEXERIL (157 patients)
DIOVAN (156 patients)
TYLENOL (156 patients)
LOVENOX (154 patients)
MULTI-VITAMIN (154 patients)
SPIRIVA (153 patients)
METOPROLOL (151 patients)
ACETYLSALICYLIC ACID SRT (151 patients)
METHADONE HCL (149 patients)
PROMETHAZINE (149 patients)
LANSOPRAZOLE (148 patients)
PARACETAMOL (148 patients)
HEPARIN (148 patients)
ULTRAM (144 patients)
MOTRIN (144 patients)
TRAZODONE (143 patients)
CITALOPRAM (142 patients)
VENLAFAXINE (142 patients)
ELAVIL (142 patients)
COLACE (142 patients)
TAMIFLU (141 patients)
VALTREX (141 patients)
AMOXICILLIN (139 patients)
HYDROCODONE (139 patients)
RISPERDAL CONSTA (137 patients)
VARENICLINE (136 patients)
ENALAPRIL MALEATE (136 patients)
VANCOMYCIN (136 patients)
REQUIP (135 patients)
REMICADE (133 patients)
TYLENOL (CAPLET) (132 patients)
INVEGA (132 patients)
WELLBUTRIN SR (132 patients)
SENNA (132 patients)
COGENTIN (131 patients)
LOPRESSOR (130 patients)
TYSABRI (130 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about AGITATION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.